Overexpression of the Wilms’ tumor 1 gene (WT1) is implicated in the prognosis of leukemia with high expression predicting disease progression in acute myeloid leukemia (AML), as well as being intensively studied as a potential molecular marker for minimal residual disease (MRD) and treatment response. This evidence concerns the gene WT1 and leukemia.